CTX-2026 / Compass Therap - LARVOL DELTA

Characterization of antibodies against BTN2A1 for Vδ2+ γδ T cell-based tumor immunotherapy (SITC 2022) - "5–8 More recently, agonist antibodies against BTN3A (e.g., clone 20.1, ICT-01 and CTX-2026) have been identified and used as a phosphoantigen-independent approach to activate Vγ9Vδ2 + T cells for targeted cell killing. Results We have also established a pre-clinical humanized tumor model using NOD scid gamma (NSG) mice and showed delayed tumor growth in mice that received 4 rounds of human Vδ2 + γδ T cell adoptive cell transfer in combination with clone 20.1 agonist antibody, which will allow further characterization of our anti-BTN2A1 antibodies. Conclusions Taken together, our study has demonstrated the potential to target BTN2A1 and BTN3A1 for Vγ9Vδ2 + T cell-based cancer immunotherapy development."

Oncology • BTN2A1 • BTN3A1

Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (Businesswire) - "CTX-8371, a PD-1 X PD-L1 Bispecific:...Initiated preparation of IND submission materials with the goal of submission of the IND in early 2022 and potential for early safety and top-line data later in 2022...Published preclinical data in the journal Science supporting the potential of CTX-2026, a novel antibody to the butyrophilin BTN3A1 in ovarian cancer tumor models...R&D expenses were $4.4 million during the fourth quarter of 2020, as compared to $3.3 million for the same period in 2019, an increase of $1.1 million or 33%. The higher costs were primarily related to manufacturing expenses and toxicological studies for CTX-8371."

Clinical data • Commercial • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models (Businesswire) - "Compass Therapeutics, Inc…announced the publication in the journal Science of preclinical data supporting CTX-2026, the Company’s novel anti-CD277 antibody product candidate. The paper describes the discovery and preclinical characterization of CTX-2026, a fully human antibody that binds to the CD277 antigen expressed on members of the butyrophilin family, including BTN3A1, and has been shown to engage two T cell subsets, gamma delta and alpha beta, to overcome the immunosuppressive tumor microenvironment associated with ovarian cancer."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer